Our obligation is to understand why an agent works and to select the right patients for treatment
To promote the development of scientific research into pioneering clinical practice, thus enabling our patients to benefit from the very latest advances in oncological research
The database contains 117 publications. These include publications both with and without an impact factor.
TOTAL IF 2008: 715.467
Herramientas de contenido
Clinical Research
The aim of the Clinical Research Program is to produce high-quality clinical research based on obtaining accreditation to conduct phase I, II and III clinical trials so that patients can gain access to new drugs being clinically assessed for efficacy.
Phase I clinical trials: pharmacokinetic and pharmacodynamic trials of cytostatic drugs and medication designed to block or inhibit specific molecular targets in tumoral cells, whether as sole agents or in combination. Some of these medications are administered to human beings for the first time.
Phase II clinical trials: trials to obtain preliminary observations of the effects of oncological drug activity on oncological pathologies, whether evaluating drugs aimed at molecular targets or new cytotoxic agents, either as sole agents or in combination.
Phase III clinical trials: trials of new chemotherapy drugs combinations, which aim to demonstrate the benefits of innovative therapeutic strategies in the treatment of tumors.
The Oncology Department at Vall d’Hebron University Hospital is home to the largest medical unit for clinical trials in Spain. Over the course of 2008, 103 clinical trials on new drugs were initiated.
Clinical Research Programs:
©2008 VALL D’HEBRON. Institut d’Oncologia. Todos los derechos reservados